NT-301 Nasal Spray Shows Promising Phase 1 Results for Parkinson's Disease OFF Episodes
核心洞察
Mikart and Nano PharmaSolutions (搜索) reported positive interim Phase 1 safety and pharmacokinetic data for NT-301, a proprietary powder nasal spray targeting Parkinson's disease (搜索) OFF episodes.
The nanodrug delivery system demonstrated dose-proportional exposure and rapid absorption with Tmax of approximately 20 minutes in healthy volunteers across 1-3 mg doses.
NT-301 utilizes NanoTransformer® technology, a patented platform that enhances drug solubility and bioavailability through nano-coating of active pharmaceutical ingredients.
Mikart, LLC and Nano PharmaSolutions (搜索), Inc. have announced positive interim safety and pharmacokinetic data from the ongoing Phase 1 clinical trial of NT-301, a proprietary powder nasal spray being developed for the treatment of Parkinson's disease (搜索) OFF episodes. The drug-device combination product has demonstrated favorable absorption characteristics and been well-tolerated by participants, with no significant adverse effects reported thus far.
Rapid Absorption Profile Demonstrates Clinical Potential
Interim blinded pharmacokinetic data from single ascending doses of NT-301 powder nasal spray from 1-3 mg demonstrated dose-proportional exposure and rapid absorption with a Tmax of approximately 20 minutes in healthy volunteers. The companies have now begun dosing of the 4 mg cohort, with investigators anticipating an even shorter Tmax at higher doses.
"Fast and reliable onset of action is critical for patients who need on-demand medicines," said Kay Olmstead, Ph.D., MBA, CEO and Co-Founder of Nano PharmaSolutions (搜索). "The NT-301 interim data reinforce the potential of NanoTransformer® technology to transform treatment for people with Parkinson's disease (搜索)."
NanoTransformer® Technology Platform
NT-301 is powered by NanoTransformer® technology, Nano PharmaSolutions (搜索)' patented nanodrug manufacturing platform that improves drug solubility, enhances bioavailability, and enables fast absorption through nano-coating of active pharmaceutical ingredients (APIs). The technology uses a patented physical vapor deposition (PVD) process to nano-coat drugs on hydrophilic excipient under ultra-high vacuum without solvents or polymers, resulting in enhanced solubility and faster absorption across a wide range of compounds.
For CNS therapies, the Nano-CNS™ nasal spray platform has a pathway to direct, rapid delivery to the brain (搜索) via olfactory and trigeminal pathways, potentially bypassing the blood-brain barrier (搜索).
Manufacturing Expansion Plans
Alongside the positive clinical data, both companies revealed plans to expand manufacturing capabilities for NanoTransformer® technology to meet anticipated demand as development progresses. NT-301 is manufactured at Mikart's GMP facility in Atlanta, with the CDMO providing comprehensive development, analytical, packaging, and manufacturing services.
"The successful application of NanoTransformer® in NT-301 highlights the strength of our product development and technical teams at Mikart," commented Nazar Elkarim, PhD, Vice President of Product Development Services at Mikart. "This collaboration not only demonstrates our ability to execute complex nanoparticle formulations at GMP scale, but also underscores how we can help accelerate the development of breakthrough therapies that address urgent unmet medical needs."
The companies are scaling up production infrastructure for NanoTransformer® technology as the Phase 1 trial continues to evaluate NT-301's safety profile and pharmacokinetic characteristics in the treatment of Parkinson's disease (搜索) OFF episodes.